MS drug improves survival

Beta-interferons produce “a significant survival advantage among people with relapsing-onset multiple sclerosis” (RRMS), according to a new study in Brain.

Researchers enrolled 5,989 people with RRMS in Canada and France. During the average follow-up of 11 years, 742 people died from any cause. The authors matched 649 of those who died with between one and 20 controls who remained alive.

After adjusting for age and use of other disease-modifying therapies (DMTs), beta-interferon was associated with a 32 per cent lower risk of mortality. RRMS patients who received more than three years’ cumulative treatment with beta-interferon showed a 56 per cent lower risk of mortality.

Treatment for between six months and three years did not influence mortality.

Additional analyses showed that the findings were similar between France and Canada, for males and females, and when the analysis included only deaths related to MS. The authors say that future studies should determine if other DMTs improve survival and whether this translates into improved quality of life.

Latest discussions

  1. Are pharmacists guinea pigs for covid19

    I work in GP dispensery and was a tech, ...

  2. Are pharmacists guinea pigs for covid19

    Looks like we are! Surgeries and dentist...

This website is for healthcare professionals, people who work in pharmacy and pharmacy students. By clicking into any content, you confirm this describes you and that you agree to Pharmacy Magazine's Terms of Use and Privacy Policy.

We use essential, performance, functional and advertising cookies to give you a better web experience. Find out how to manage these cookies here. We also use Interest Based Advertising Cookies to display relevant advertisements on this and other websites based on your viewing behaviour. By clicking "Accept" you agree to the use of these Cookies and our Cookie Policy.